Centene vs Cvs Health
CNC and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNC and CVS compare
Cvs Health is the larger company, worth 3.3 times as much as Centene ($114B against $34.9B).
On earnings, Cvs Health is cheaper: it trades at 10.4× trailing earnings, against 24.1× for Centene.
Centene grew revenue faster over the last twelve months (9.7% versus 6.7% for Cvs Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with 0.72% at Centene.
Cvs Health pays a dividend yielding 2.2%; Centene does not pay one.
Cvs Health scores higher on the StockData Score (19 against 8 for Centene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNC | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $34.9B | $114B |
| Share price | $70.48 | $89.52 |
| Change, 1 year | 106% | 15.5% |
| Change, 5 years | −3.5% | −3.9% |
| Beta (5Y) | 0.50 | 0.50 |
| Employees | 61K | 300K |
| StockData Score | ||
| Total score | 8 | 19 (better) |
| Valuation score | 2 | 6 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 24.1× | 10.4× (better) |
| P/S | 0.2× (better) | 0.3× |
| P/B | 1.6× | 1.4× (better) |
| EV/EBITDA | 12.0× | 8.2× (better) |
| P/FCF | 8.8× | 7.4× (better) |
| FCF yield | 11.3% | 13.6% (better) |
| Fair value | $69.68 | $129.23 |
| Margin of safety | −1.1% | 30.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.7% (better) | 6.7% |
| Revenue growth, 5Y average | 11.9% (better) | 8.4% |
| Net income growth (TTM) | – | 2253% |
| EPS growth (TTM) | – | 2158% |
| EPS growth, 5Y average | – | −23.9% |
| Profitability | ||
| Gross margin | 7.9% | 44.2% (better) |
| Operating margin | 0.49% | 3.6% (better) |
| Net margin | 0.72% | 2.6% (better) |
| FCF margin | 1.9% | 3.7% (better) |
| Return on equity | 6.8% | 14.4% (better) |
| Return on invested capital | 4.6% | 10.8% (better) |
| Financial health | ||
| Debt / equity | 0.70 (better) | 0.75 |
| Net debt / EBITDA | −3.60 | 2.34 (better) |
| Interest coverage | 1.6× | 4.9× (better) |
| Current ratio | 1.16 (better) | 0.85 |
| Altman Z-score | 3.28 (better) | 2.51 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 2.2% |
| Payout ratio | – | 31.0% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 5.9% |
| Buyback yield | 0.07% | – |
| Shareholder yield | 0.07% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 98.6% | 89.2% |
| Held by insiders | 0.79% | 0.43% |
| Insider net buying, 12 months | −$14.6M (better) | −$322M |
| Superinvestors holding | 3 | 6 (better) |
| Short interest, % of float | 2.1% | 1.4% |
Go deeper
- CNC stock overview
- CNC income statement
- CNC valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.